Table 4.

The effects of various levels of zinc-methionine supplementation on lipid parameters

Treatments				Control	Lipid Parameters
PCO-ZM175	PCO-ZM75	PCO-ZM25	PCO
90.80±11.34(++)	106.00±13.22(+)	128.20±11.34(*)	135.00±22.90(*)	98.20±16.9	TG (mg/dl)
41.20±4.49(++)	37.20±6.01(+)	29.80±6.45(*)	27.00±4.39(*)	36.80±7.25	HDL- C (mg/dl)
2.23±0.41(++)	2.90±0.50(+)	4.45±0.94(*)	5.23±1.94(*)	2.79±0.93	TG/ HDL

The data are offered as mean±SD *, **, and ***, respectively show significant differences at the levels of P<0.05, P<0.01, and P<0.001, between the healthy control and PCO groups. +, ++, and +++, showed significant differences between zinc-methionine-treated PCO groups and PCO control group at the levels of P<0.05, P<0.01, and P<0.001, respectively. TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; Control: Healthy control group; PCO: Polycystic ovary control group; PCO-ZM 25, PCO-ZM 75 and PCO-ZM175 groups: polycystic groups treated with 25, 75, and 175 mg zinc-methionine, respectively